3rd December 2008, London: College Hill's Life Sciences team has been appointed by Abraxis Bioscience (NASDAQ: ABII) to support the European launch of its product ABRAXANE®, with initial focus in the UK and Germany. College Hill's remit includes both corporate and product-based public and media relations.
Abraxis is a fully integrated biotechnology company focused on delivering progressive therapeutics and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. With headquarters in Los Angeles, California, USA, Abraxis also has operations in Canada, China, Switzerland and the UK. Its lead product ABRAXANE® is the world's first and only albumin bound nanoparticle chemotherapeutic compound which is based on its proprietary tumour targeting system known as the nab™ platform. ABRAXANE® has been approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of patients with metastatic breast cancer.
Commenting on the win, Sue Charles, Managing Partner Life Sciences said: "We are extremely pleased to have been chosen to support Abraxis with its European launch of ABRAXANE®. We are confident that our expertise in the of area of oncology together with our well established media relations contacts within the UK and Germany will deliver added value to the launch of ABRAXANE® in Europe."
Sue Charles, Managing Partner, Life Sciences will lead the account with Adam Michael, Senior Account Director leading the team in the UK, and Dr Douglas Pretsell, Senior Account Director leading the team in Germany. Providing client and project management will be Cosima Zerdik, Account Manager, with Dr Eileen Paul, Projects Director, as head of writing supported by Dr Ify Sargeant.
For further information:
Sue Charles, Managing Partner
UK: +44 (0)20 7457 2020/ +44 (0)7968 726 585
Australia: +61 (0)457 196 222